补充C5a和C5a受体1在焦点细分型淋巴结核硬化中调解淋巴结核损伤
Xiao-Jie Gong1, Jing Huang1, Yue Shu1
1Renal Division, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of CKD Prevention and Treatment, Ministry of Education of China; Research Units of Diagnosis and Treatment of Immune-mediated Kidney Diseases, Chinese Academy of Medical Sciences, Beijing, China.
补充激活驱动着焦点细分性淋巴结核硬化 (FSGS). 通过对抗剂向细胞和上皮细胞 (PECs) 中的C5a-C5aR1通路,对FSGS显示出治疗的前景.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 免疫学 免疫学 免疫学
- 补充系统生物学 补充系统生物学
背景情况:
- 补充剂激活与焦点细分性淋巴结核硬化 (FSGS) 的进展有关.
- 在FSGS中补充诱导的细胞损伤和上皮细胞 (PEC) 激活的机制尚不清楚.
研究的目的:
- 调查C5a-C5aR1轴在FSGS病原发生中的作用.
- 评估FSGS中C5aR1抗剂的治疗潜力.
主要方法:
- 在FSGS患者中评估质C5aR1表达.
- 使用Adriamycin诱导的脏病小鼠模型.
- 检查了C5aR1抗剂对PEC和podocyte在体外和体内的作用.
主要成果:
- 在FSGS脏中,C5aR1过度表达,与疾病严重程度和预后相关.
- 在小鼠中,C5aR1抗剂治疗减弱了蛋白尿,损伤和血球硬化.
- 反对者减少了PEC激活/扩散,减轻了细胞损失,并减少了补体沉积.
- 实验室研究表明,C5aR1抗剂逆转了FSGS血诱导的细胞损伤和调节的PEC反应.
结论:
- 细胞和PEC上的C5a-C5aR1轴在FSGS中具有病原性.
- C5aR1对抗性为FSGS提供了一个潜在的治疗策略.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11:47Using 2-Photon Microscopy to Quantify the Effects of Chronic Unilateral Ureteral Obstruction on Glomerular Processes
Published on: March 4, 2022
相关概念视频
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Intracellular Signaling Affects Focal Adhesions
Some...
Glomerular Filtration Rate and its Regulation
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
